Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Bristol Myers Squibb has signed a research deal worth up to $3 billion with Century Therapeutics, deepening its commitment to cell therapy as it works to…
Bristol Myers Squibb has struck a deal worth as much as $3 billion with Century Therapeutics, a Philadelphia biotech developing cell therapies derived from…
Bristol-Myers Squibb notified the Company on December 12, 2024 that it would be terminating the Collaboration Agreement in its entirety without cause after the…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
BMS and Century Therapeutics entered a strategic collaboration to develop and commercialize up to four iPSC-derived allogeneic NK and T-cell therapy programs in hematologic malignancies and solid tumors. Century received $100M upfront plus a $50M equity investment, with up to $3B in additional payments plus royalties. UPDATE (terminated): On December 12, 2024 BMS notified Century that it would terminate the collaboration in its entirety, without cause, following an internal portfolio-prioritization review; the termination became effective March 12, 2025. Century recognized the remaining $109.2M deferred transaction price as one-time collaboration revenue in Q1 2025, with no further collaboration revenue expected. Century has since refocused lead asset CNTY-101 from oncology toward autoimmune disease (CALiPSO-1).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Century Therapeutics Inc. (this deal) | 2022 | $3.1B | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2022 deals · Bristol-Myers Squibb Company deals · Hematology deals